Utility of repeating assessments in chronic back pain pts suspected of early axSpA? 2 year study found a modest increase in new axSpA diagnosis after 2 years Yield of repeating MRI is low but can be considered in B27+ males @RheumNow #ACR23 Abs#0845 https://t.co/TgSEztUkTm

DRESS-PS study LTE. 12 month observational extension. 114 patients PsA/AxSpA. Essentially patients TNFi tapered or not in T2T fashion. TNFi dose remained lower in tapering group but it is consistently creeping back up. Abstr#0775 @RheumNow #ACR23 https://t.co/aYoOl6Ccin https://t.co/BtMR95lIfs

Abs#518 @RheumNow #ACR23 Deodhar: TOFA in AS, by b/l CRP levels 30% nml CRP (<5 mg/L) v 70% Elevated At wk 12, TOFA >> PBO regardless of b/l CRP Difference in response: greater in pts w elevated CRP Safety rates: elev. CRP c/w PBO, but nml CRP had trend of high AEs for tofa v PBO https://t.co/b9NRNkU8ub

Are Long-term NSAIDs safe in AS? Ab#0528 #ACR23 @RheumNow 19,775 AS pts vs 59,325 controls. Incidence of 16.9, 13.8 per 1,000 person-yrs, respectively Long-term use of NSAIDs increased risk of CVD in non-AS control (aHR 1.64), but did NOT in AS pts (aHR 1.06)

2 yrs extension of DRESS-PS study 100+ pts w/ PsA and AxSPA -70% LDA state in both Ctrl & Intervention gps -strong recovery after relapse No difference efficacy protocolized & routine care tapering but inferior TNFi use (52 vs. 77%) in Intervention gp @RheumNow #ACR23 ABST0775 https://t.co/V2DqCjT0w3

Upadacitinib on wearable device-measure activity SELECT-AXIS 2 Abs#0530 #ACR23 @RheumNow UPA had numerically higher mean daily step counts than PBO 11% improvement v PBO at wk 14 (diff of 345 steps/day) Sedentary pts: 22% improvement in daily step count from b/l on UPA (4% PBO) https://t.co/Gq91TmvfZC

What are effects of TNFi on Lipids in AxSpA? Ab#0531 #ACR23 @RheumNow 320 pts w AS - retrosp cohort, first-line TNFi, not on lipid Rx Chol and TG increase in 1st 3 mos of treatment. LDL & HDL: no signif change Inflam markers/Lipids correlated - suspect due to anti-inflamm effect https://t.co/qT5qUEOEvO

Abs#0501 @RheumNow #ACR23 Uveitis in SpA, from Greece AxSpA: 11.7% Uveitis. RF: HLA-B27 (OR 4.15), periperhal arthritis (OR 3.05) PsA: 2.7% Uveitis. Ass w/ SpA FHx, Axial dis at dx, disease duration Permanent vision loss in 16% AxSpA, 30% PsA pts, all with recurrent uveitis